You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge.

Date Reviewed: November 19, 2017

Measure Info

MIPS 008NQF 0083CMS 008NQF EndorsedCQMC Core Measure
Measure Type: 
Process
Measure Steward: 
Physician Consortium for Performance Improvement
Clinical Topic Area: 
Heart Failure

Care Setting: 
Home Care
Inpatient
Outpatient
Post-Acute Care
Data Source: 
Electronic Health Records
Registry

ACP supports QPP measure 008: “Heart Failure: Beta-blocker therapy for Left Ventricular Systolic Dysfunction” because the balance of evidence shows that long-term treatment with beta-blockers can lessen the symptoms of heart failure, improve the clinical status of patients, and enhance the patient’s overall sense of well- being. Furthermore, the measure aligns with current guidelines and represents high-value care for patients with chronic heart failure.